Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain
Image File
Original HTML

Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain

- Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®.

- Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.1

AACHEN, Germany, Oct. 27, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand.

The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for retreatment, the numerical difference favoured Qutenza® but did not reach statistical significance. In the extension phase of the trial, in which up to 4 retreatments were allowed, Qutenza® achieved a statistically significantly greater reduction in API than the control treatment over weeks 2-42. Safety findings were consistent with previous Qutenza® trials and no new safety signals were observed. These data support the well-established efficacy and safety profile of Qutenza®.2,3

"Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control," said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. "As IASP shines a global spotlight on neuropathic pain at this year's congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems."

"Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice," said Uli Brödl, Chief Scientific Officer, Grünenthal. "These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain."

Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.4

Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5 It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.6

About the RISE trial2,3

The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain.

It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more.

Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%).

The trial had two primary endpoints:

- Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12.

- Change in 24-hour API from baseline to the average score at Week 12.

The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal's U.S. subsidiary.

About post-surgical neuropathic pain

Post-surgical neuropathic pain (PSNP) is defined as chronic pain with neuropathic characteristics that develops or increases after surgery and persists beyond the normal healing process. It is thought to arise, at least in part, from nerve injury and pain sensitisation associated with surgery.7

The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.8,9,10

About Qutenza®

In Europe, Qutenza® (capsaicin) is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5

Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.6

Qutenza® is a topical TRPV1 agonist, designed to provide neuropathic pain relief for up to three months through defunctionalisation of nociceptors and nerve fibre regeneration.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better â and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of â¬1.8 billion.

More information: www.grunenthal.com

Follow us on LinkedIn & Instagram

For further information, please contact:

Matt Crabb, Head of Global Communications (Interim) at Grünenthal

References

1 Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1â6.

2 Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.

3 Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.

4 Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42â56.

5 European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc

6 US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf

7 Correl D. F1000Res. 2017;6:1054.

8 Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1â4.

9 Macrae WA. Br J Anaesth. 2008;101:77â86.

10 Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12â14.

SOURCE Grünenthal Group

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302921015
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): The target contains an unsupported medical/regulatory claim: it asserts that post-surgical neuropathic pain is not among Qutenza's approved indications, but the source does not state this and the broad European indication for peripheral neuropathic pain could encompass PSNP.
Source Name
Unknown Company
Original Summary

<p>Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.1 AACHEN, Germany, Oct. 27, 2026...</p>

Original Link
Original Source
Image URL
https://www.qutenza.com/og_image.jpg
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Grünenthal's Qutenza Meets Primary Endpoint in Phase III RISE Trial", "body_html": "<p><strong>AACHEN – [CURRENT_DATE] --</strong> Grünenthal's Qutenza capsaicin patch achieved a statistically significant reduction in average pain intensity (API) over weeks 2-12 versus control in the 409-patient Phase III RISE trial, but missed significance on the second primary endpoint at week 12.</p><h5>RISE trial hits one of two primary endpoints in post-surgical neuropathic pain</h5><p>The trial (NCT04967664) compared Qutenza 179mg (8% capsaicin, 60-minute application) with a low-dose 0.04% capsaicin control patch. Patients had moderate to severe post-surgical neuropathic pain, an API score of 4 or higher, pain lasting 6 to 60 months after surgery and a DN4 interview score of 3 or higher.</p><p>At week 12, when patients would typically return for retreatment, the numerical difference favoured Qutenza but was not statistically significant. That was the trial's second primary endpoint.</p><h5>Extension phase with up to four retreatments shows significant benefit through week 42</h5><p>In the extension phase, Qutenza delivered a statistically significantly greater API reduction than control over weeks 2-42. Up to four retreatments were permitted. Safety findings matched earlier Qutenza trials, and no new safety signals emerged.</p><p>The data were presented as late-breaking posters at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand.</p><h5>Grünenthal frames post-surgical neuropathic pain as an under-recognised market</h5><p>Chief Scientific Officer Uli Brödl said the condition has been relatively understudied and goes under-recognised in clinical practice. He added that the results build on existing evidence for Qutenza.</p><p>Prof. Patrice Forget of the University of Aberdeen said the trial provides encouraging evidence of clinically meaningful, sustained pain reduction for up to 42 weeks.</p><p>The source describes the condition as affecting millions of patients every year, with pain lasting months or years after surgery. It can also bring depression, anxiety and difficulty with daily activities.</p><h5>Averitas Pharma sponsors the trial as Qutenza holds existing approvals in Europe and the US</h5><p>Averitas Pharma, Inc., Grünenthal's U.S. subsidiary, is the primary sponsor. Post-surgical neuropathic pain is not among Qutenza's approved indications. In Europe the patch is approved for peripheral neuropathic pain in adults, alone or combined with other pain medicines. In the US it is approved for neuropathic pain associated with postherpetic neuralgia and with diabetic peripheral neuropathy of the feet in adults.</p>", "meta_description": "Grünenthal's Phase III RISE trial (n=409) shows Qutenza cut post-surgical neuropathic pain over weeks 2-12, but missed significance at week 12 alone.", "seo_keywords": "Grünenthal, Qutenza, RISE trial, post-surgical neuropathic pain, capsaicin patch, Phase III, IASP 2026, Averitas Pharma, pain management", "companies": ["Grünenthal", "Averitas Pharma"], "industries": ["Biopharmaceuticals"], "markets_regions": ["Europe", "United States"], "news_type": ["clinical_trial_results"], "products": ["Qutenza"], "themes": ["clinical_research", "pain_management"], "events": ["IASP 2026 World Congress on Pain"], "cta_text": "Read the full Grünenthal announcement on Qutenza RISE Phase III results", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
d96acbc62a8ffb6847aff55378b75c2a